

Half-Year Media Conference 2020



13 August 2020

Agenda

- Opening Statement
 Jeannine Pilloud, CEO
- Financial Review H1 2020
 Dominik Maurer, CFO
- Ascom during Covid-19 crisis
 - Jeannine Pilloud, CEO
 - 2 Representatives of Slingeland Hospitals (NL)
- Outlook
 Jeannine Pilloud, CEO
- Q&A





Today's Presenters of Ascom



JEANNINE PILLOUDCEO




DOMINIK MAURERCFO



Our Commitment

As per Annual Media Conference 5 March 2020



Execution Highlights



Business stabilized through **lean organization** and **strong leadership team** with ambitious goals



Regions with full end-to-end P&L responsibility



Set up of Clinical Solutions Team



Transformation Program SIFOX (Simplify, Focus, Execution) to stabilize and transform the business is advancing well - current focus on simplification and realignment of go-to-market and efficient delivery model



First Half-Year 2020 at a Glance

Decent Performance in H1 Despite the Covid-19 Crisis



2.8% net revenue growth (at constant currencies)

Substantial improvement of gross profit margin (47.8%) and EBITDA (+ CHFm7.7 vs. H1 2019 at constant currencies)



Positive development in particular in USA & Canada as well as in UK and Nordics



France with a temporary negative impact as market has been hit hard by severe lock-down



Incoming orders with slight increase of 1.1% vs. H1 2019 at constant currencies in spite of Covid-19



Solid double-digit order backlog increase



Ascom benefited from emergency activities in certain markets during the Covid-19 crisis, which compensated partially for Covid-related project delays



Ascom with improved balance sheet and positive net cash position





Financial Review H1 2020




Dominik Maurer, CFO

Key Figures H1 2020

| At Actual Currencies | | H1 2020 | H1 2019 | Variance to PY | |
|----------------------|-----------------|-------------------------------------|-------------------------------------|----------------|-----------|
| | | HI 2020 | H1 2019 | СС | CHF |
| | Net revenue | 133.4 CHFm | 137.0 CHFm | +2.8% | -2.6% |
| | Incoming orders | 154.8 CHFm | 161.7 CHFm | +1.1% | -4.3% |
| | Order backlog | 194.3 CHFm | 172.1 CHFm | +17.6% | +12.9% |
| | EBITDA | 8.4 CHFm (EBITDA margin of 6.3%) | 1.4 CHFm (EBITDA margin of 1.0%) | +7.7 CHFm | |
| | Group profit | -0.3 CHFm | 6.5 CHFm* | | -6.8 CHFm |
| | FTE | 1,269 | 1,306 | -2.8% | -2.8% |



Incoming Orders Increased by 2% (at Constant Currencies w/o OEM)



H1 2020 Revenue Development

In CHFm Revenue growth at constant currencies: +2.8% 140.9 3.9 137.0 -7.5 133.4 H1 2019 Revenue Revenue Growth H1 2020 Revenue at **Currency Effect** H1 2020 Revenue **Constant Currencies**



Revenue H1 2020 – Regional Development

Deviations at Actual Currencies (%-CHF) and at Constant Currencies (%-cc)

| Region | Revenue | Variance to PY | | |
|----------------|---------|----------------|--------|--|
| Region | CHFm | %-cc | %-CHF | |
| DACH | 22.5 | +0.0% | -3.0% | |
| France & Spain | 7.6 | -29.2% | -32.7% | |
| Netherlands | 24.4 | -1.5% | -6.9% | |
| Nordics | 19.2 | +15.3% | +4.9% | |
| UK | 6.7 | +22.4% | +15.5% | |
| USA & Canada | 26.1 | +13.0% | +9.7% | |
| Rest of World | 18.6 | +6.4% | -0.5% | |
| ОЕМ | 8.3 | -8.2% | -14.4% | |




H1 2020 – Income Statement

| In CHFm | 2020 | % | 2019 | % | Variance %-cc | Variance %-CHF |
|-----------------------------|--------|---------|--------|---------|------------------|-------------------|
| Net Revenue | 133.4 | 100.0% | 137.0 | 100.0% | 2.8% | (2.6%) |
| Cost of Sales | (69.7) | (52.2%) | (75.7) | (55.3%) | (3.2%) | (7.9%) |
| Gross Profit | 63.7 | 47.8% | 61.3 | 44.7% | 10.3% | 3.9% |
| Marketing and Sales | (33.9) | (25.4%) | (40.7) | (29.7%) | (12.3%) | (16.7%) |
| Research and Development | (17.9) | (13.4%) | (15.8) | (11.5%) | 20.3% | 13.3% |
| Administration | (10.4) | (7.8%) | (9.4) | (6.9%) | 14.9% | 10.6% |
| Other Operating Expenses | (0.5) | (0.4%) | (0.8) | (0.6%) | 12.5% | (37.5%) |
| EBIT | 1.0 | 0.7% | (5.4) | (3.9%) | | |
| EBITDA | 8.4 | 6.3% | 1.4 | 1.0% | | |
| Group Profit for the Period | (0.3) | (0.2%) | 6.5* | 4.7% | | |




EBITDA Development





Cash Flow Development





Balance Sheet

| | 2020 30-Jun | 2019 31-Dec | 2019 30-Jun | 2018 31-Dec |
|-------------------------|----------------|----------------|----------------|----------------|
| Cash & Cash Equivalents | 29.2 | 18.2 | 14.2 | 21.2 |
| Borrowings | 28.0 | 40.0 | 25.0 | 20.0 |
| Net Cash | 1.2 | (21.8) | (10.8) | 1.2 |
| Net Working Capital | 44.2 | 68.2 | 61.3 | 74.5 |
| Total Assets | 200.6 | 214.2 | 198.6 | 218.4 |
| Total Equity | 61.2 | 63.2 | 70.0 | 83.2 |
| Equity Ratio | 30.5% | 29.5% | 35.2% | 38.1% |





Ascom During Covid-19 Crisis



Jeannine Pilloud, CEO & 2 Representatives of Slingeland Hospital (NL)

Highlights and Lowlights During Covid-19 Crisis

Highlights



Win of several deals in both, Healthcare and Enterprise sector



Ascom revenue benefited from emergency activities in certain markets compensating some Covid-19 related project delays



Good staff morale and **team spirit** during the Covid-19 crisis



Very few employees infected by Covid-19

Lowlights



Covid-19 crisis hit in particular the French market hard — considerable impact on French business




Some projects were delayed into H2



International collaboration and support will be impacted for longer period; no prognosis possible at today's state



Selection of Substantial Wins in H1 2020





Showcase Slingeland Hospital



Slingeland Project



GABY PONS VAN DIJKPHD, MD, NEUROLOGIST
SLINGELAND HOSPITAL



NICK SCHOENAKER

MSC, NURSE SPECIALIST NEUROLOGY

SLINGELAND HOSPITAL



MARIO DE LIJSTER
PROJECT LEAD
ASCOM NETHERLANDS





Smart Monitoring:

Improving the quality of care through continuous monitoring of vital signs

August 2020

Slingeland Hospital

Gaby Pons van Dijk, PhD, MD, Neurologist

Nick Schoenaker Msc, Nurse Specialist Neurology



Slingeland Hospital

The challenge: Aging population, migration of youth

The Goal: "Achterhoek" the healthiest region in the Netherlands

Thus: Relieving pressure on the healthcare system

The method: Quadruple aim

Generating and using data

Communication

Inside Slingeland: Smart monitoring





Success Factors for Better Patient Outcome


Continuous measurement of vital signs

Early detection of changing condition

Decision support via artificial intelligence / clinical decision support system

Treat before actual incident happens

- Shorter length of stay
- ✓ Better patient outcome





Continuous Vital Sign Measurements

Area

Components

Requirements

Heart rate

- Free choice in sensors
- Respiratory rateBlood pressure
- Oxygen saturation

Data integration



Measure

Early Warning Score

- Hospitals "own" algorithms
- Medical device direction / Medical device regulation certification



- With caregiver
- Central control room
- Integration with Nurse call
- Clinical workflow knowledge

Ascom Solution

Digistat

(Software & Services)

Digistat

(Software & Services)

Unite Myco 3 Consultancy





First patient monitored: March 9, 2020



Project Sensing Clinic in Covid-19 Positive Patients

"In my 25 years as a pulmonologist, I've never seen people deteriorate as quickly with a viral infection as I did with corona.."


"We sometimes get people in who say: I don't really feel that distressed at all', says pulmonologist Pascal Wielders of the Catharina Hospital in Eindhoven. But in the meantime, we see from the oxygen value in their blood, that they are. What's more, we see that they're starting to turn blue.."

Volkskrant: 27-03-2020

Ascom changed the setup and algorithm, we changed workflow: First inclusion of Covid-19 patients on 1 April 2020




Trends of Vital Signs During Covid-19 Outbreak (Patient Admitted to ICU)





Next Steps With Our Partners: Rollout From a Local Setup to a National Standard








Outlook



Jeannine Pilloud, CEO

Outlook 2020 Reiterated

As per Annual Media Conference 5 March 2020



This is based on the assumption that the **Covid-19 crisis will not worsen again**





Q&A

ascom



Next Event – Annual Media Conference on 11 March 2021



Restaurant Metropol, Zurich

LEGAL DISCLAIMER

This document contains specific forward-looking statements, e.g. statements including terms like "believe", "expect" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Ascom and those explicitly presumed in these statements.

Against the background of these uncertainties readers should not rely on forward-looking statements. Ascom assumes no responsibility to update forward-looking statements or adapt them to future events or developments.

